Evidence map›Paper›PMID 39972168›Full record

ArticleNature structural & molecular biology2025

Structural insights into TRPV2 modulation by probenecid.

Julia A Rocereta, Toni Sturhahn, Ruth A Pumroy, Tabea C Fricke, Christine Herzog, Andreas Leffler, Vera Moiseenkova-Bell

Abstract read
PubMed Publisher
In one paragraph

Article in Nature structural & molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Determinants for Activation of the Ion Channel TRPV3 by Weak Acids.International journal of molecular sciences · 2025
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julia A RoceretaDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Toni SturhahnDepartment of Anesthesiology and Intensive Care Medicine, Hannover Medical School, Hannover, Germany.
Ruth A PumroyDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-6200-6083
Tabea C FrickeDepartment of Anesthesiology and Intensive Care Medicine, Hannover Medical School, Hannover, Germany.
Christine HerzogDepartment of Anesthesiology and Intensive Care Medicine, Hannover Medical School, Hannover, Germany.
Andreas LefflerDepartment of Anesthesiology and Intensive Care Medicine, Hannover Medical School, Hannover, Germany. Leffler.Andreas@mh-hannover.de.ORCID http://orcid.org/0000-0003-1121-6387
Vera Moiseenkova-BellDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. vmb@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-0589-4053

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transient receptor potential vanilloid 2 (TRPV2) cation channel is a key player in cardiovascular physiology and pathophysiology. Probenecid (PBC), an FDA-approved uricosuric agent thought to activate TRPV2, has shown promise in enhancing cardiovascular function in both preclinical and clinical studies. Here our electrophysiological data reveal that PBC significantly potentiates rat TRPV2 to known stimuli, and cryo electron microscopy structures show that PBC directly interacts with rat TRPV2 in a previously unidentified intracellular binding pocket. PBC binding at a conserved TRPV2-specific histidine prevents the channel from taking on the inactivated carboxyl-terminal conformation. This effect extends to TRPV1 and TRPV3 channels when glutamine is substituted with histidine at the corresponding position, increasing their sensitivity to PBC. While PBC alone does not induce TRPV2 opening, its combination with 2-aminoethoxydiphenyl borate enables the channel to adopt an intermediate, potentiated state. Our results offer insights into potential therapeutic advancements for TRPV2 through this pocket.

Indexed as

ProbenecidTRPV Cation ChannelsAnimalsBinding SitesCryoelectron MicroscopyHEK293 CellsHumansModels, MolecularProtein BindingRatsProbenecidTrpv2 protein, ratTRPV Cation Channels

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.